Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific share repurchase transaction executed on June 17, 2014, authorized by shareholders at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 190,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,588.50 pence per share; lowest price paid was 1,582.50 pence per share.
- Treasury Holdings (Settled): 500,983,770 shares (9.36% of total issued share capital).
- Treasury Holdings (Including Unsettled): 501,889,179 shares (10.35% of current total voting rights).
- Shares in Issue: 4,849,928,359 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 190,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.35% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (500,983,770 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.35% held in treasury including unsettled shares).
- Check the number of shares in issue (4,849,928,359) for use in determining disclosure thresholds under FCA rules.
- Review the price paid per share (1,582.50 to 1,588.50 pence) against market prices on June 17, 2014.